Mustang Bio Announces $9.28 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-103 in HER2-Positive Breast Cancer with Brain Metastases


You May Also Like

Peregrine Pharmaceuticals to Present at Two Upcoming Cancer Immunotherapy Conferences

TUSTIN, Calif., Jan. 20, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a ...

Collegium Announces Promotion of Scott Dreyer to CCO

CANTON, Mass., July 10, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced ...